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T-cell protein tyrosine phosphatase (TCPTP) exists as two forms generated by alternative splicing: a 48-kDa
endoplasmic reticulum (ER)-associated form (TC48) and a 45-kDa nuclear form (TC45). To identify TCPTP
substrates, we have generated substrate-trapping mutants, in which the invariant catalytic acid of TCPTP
(D182) is mutated to alanine. The TCPTP D182A substrate-trapping mutants were transiently overexpressed
in COS cells, and their ability to form complexes with tyrosine-phosphorylated (pTyr) proteins was assessed.
No pTyr proteins formed complexes with wild-type TCPTP. In contrast, TC48-D182A formed a complex in the
ER with pTyr epidermal growth factor receptor (EGFR). In response to EGF, TC45-D182A exited the nucleus
and accumulated in the cytoplasm, where it bound pTyr proteins of ;50, 57, 64, and 180 kDa. Complex
formation was disrupted by vanadate, highlighting the importance of the PTP active site in the interaction and
supporting the characterization of these proteins as substrates. Of these TC45 substrates, the ;57- and
180-kDa proteins were identified as p52Shc and EGFR, respectively. We examined the effects of TC45 on EGFR
signaling and observed that it did not modulate EGF-induced activation of p42Erk2. However, TC45 inhibited
the EGF-induced association of p52Shc with Grb2, which was attributed to the ability of the PTP to recognize
specifically p52Shc phosphorylated on Y239. These results indicate that TC45 recognizes not only selected
substrates in a cellular context but also specific sites within substrates and thus may regulate discrete signaling
events.
Protein tyrosine phosphatases (PTPs) are a diverse family of
enzymes characterized by the consensus sequence (I/V)HCXA
GXXR(S/T)G, which contains the catalytically essential Cys
and Arg residues. PTPs can be subdivided into transmem-
brane, receptor-like, and intracellular enzymes. Intracellular
PTPs are often modular molecules containing structural motifs
such as Src homology 2 (SH2) domains, PEST sequences, and
band 4.1 domains on either the N- or C-terminal side of their
catalytic domains (55, 58). In most cases, the biological func-
tion of individual PTPs remains elusive. To understand the
biological roles of this diverse family of enzymes, the identifi-
cation of their physiological substrates is of paramount impor-
tance.
T-cell PTP (TCPTP) is a ubiquitous PTP originally isolated
from a human peripheral T-cell cDNA library (12, 13). Al-
though TCPTP was one of the first PTPs to be cloned, its
biological function remains unknown. The TCPTP cDNA en-
codes a 48-kDa protein (TC48) that displays 65% sequence
identity overall and 74% sequence identity within the con-
served catalytic domain with PTP1B, the prototypic PTP (4, 9,
56, 57). Like PTP1B (17), TC48 is targeted to the endoplasmic
reticulum (ER) by a stretch of hydrophobic residues at the
extreme C terminus (12, 35). Alternative splicing of the
TCPTP transcript gives rise to a 45-kDa form of the enzyme
(TC45) which lacks the hydrophobic C-terminal tail (residues
382 to 418) (7, 40, 54) and is targeted to the nucleus by a
bipartite nuclear localization sequence (35, 53, 54). Therefore,
TC48 and TC45 have the same catalytic domain but are tar-
geted to two distinct sites, the ER and the nucleus, respectively
(35).
As a first step toward understanding the function of TCPTP,
we have used a substrate-trapping approach in which the in-
variant PTP catalytic acid (Asp 181 in PTP1B and Asp 182 in
TCPTP), which serves as a general acid catalyst to protonate
the tyrosyl leaving group in the substrate, has been mutated to
Ala (16, 19). We have shown previously that mutation of the
PTP catalytic acid yields an enzyme in which catalytic activity is
substantially impaired but affinity for substrate is largely unaf-
fected (16, 19). These substrate-trapping mutants can thus
form stable complexes with tyrosine-phosphorylated (pTyr)
substrates in vivo (16). We have now expressed D182A mutant
forms of TC48 and TC45 in COS cells and isolated complexes
containing the mutant TCPTPs and their trapped substrates.
Despite the fact that the TCPTP variants have identical cata-
lytic domains, the TC48-D182A and TC45-D182A substrate-
trapping mutants precipitated distinct pTyr proteins as well as
substrates in common. We show that the TC48-D182A mutant
remained associated with the ER, whereas the TC45-D182A
substrate-trapping mutant underwent a change in localization,
exiting the nucleus and accumulating in the cytoplasm in re-
sponse to epidermal growth factor (EGF). We have demon-
strated that TC48-D182A formed a complex with the EGF
receptor (EGFR) in the ER, whereas in contrast, the ER-
localized PTP1B recognized EGFR and an additional pTyr
protein of ;60 kDa, consistent with a difference in the intrinsic
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substrate specificity of these closely related enzymes. We have
shown that following EGF stimulation and exit of TC45 from
the nucleus, EGFR, p52Shc, and two unidentified pTyr proteins
are specific substrates of TC45. Furthermore, TC45 recognized
specifically p52Shc phosphorylated on tyrosine 239 but not ty-
rosine 317. Our data suggest that both localization and inher-
ent substrate specificity contribute to the substrate preference
displayed by TCPTP in vivo.
MATERIALS AND METHODS
Materials. Recombinant human EGF was purchased from Genzyme Diagnos-
tics (Cambridge, Mass.), human alpha and beta interferons (IFN-a and -b),
recombinant human IFN-g, and cycloheximide were purchased from Sigma (St.
Louis, Mo.), and 4,5-dianilinophthalimide (DAPH) was purchased from
Research Biochemicals International (Natick, Mass.). The following constructs
were generously provided by various colleagues: glutathione S-transferase
(GST)–Grb2 pMT3 and hemagglutinin (HA)-p42Erk2 pJ3H by L. Feig (Tufts
University, Boston, Mass.) and J. Chernoff (Temple University, Philadelphia,
Pa.), respectively, c-Src Y527F pMIKneo by R. Birge (Rockefeller University,
New York, N.Y.), and RasV12 pDCR and Raf-CAAX pcDNA3 by L. Van Aelst
(Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Antigen for the
generation of the monoclonal anti-pTyr antibody G98 (subtype immunoglobulin
M [IgM]) was produced as described previously (30) and provided by A. J.
Rossomando (Bayer Pharmaceuticals, West Haven, Conn.). The following anti-
bodies were kindly provided: polyclonal affinity-purified anti-TCPTP antibody
6228 (35) by J. A. Lorenzen and E. H. Fischer (University of Washington,
Seattle), monoclonal anti-TCPTP antibody CF4 by D. Hill (Calbiochem Onco-
gene Research Products, Cambridge, Mass.), rabbit polyclonal anti-EGFR serum
1964 by G. Gill (University of California, San Diego), and anti-Src ascites D710
by J. Bolen (DNAX, Palo Alto, Calif.).
Cell culture and transfections. COS1, HeLa, and NIH 3T3 cells were cultured
at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100
mg/ml). Where indicated, COS1 cells were serum starved for 24 h in DMEM
containing 0.1% FBS, penicillin, and streptomycin. COS1 cells were seeded at
6 3 105 per 10-cm-diameter dish, or 2.0 3 105 cells per 6-cm-diameter dish, ;24
h prior to transfection. Cells were transfected by the calcium phosphate precip-
itation method using TCPTP- or PTP1B-pMT2 plasmid DNA at 20 mg per
10-cm-diameter dish or 5 mg per 6-cm-diameter dish. A fine DNA-calcium
phosphate precipitate was obtained, and at 5 to 6 h, cells were washed three
times with phosphate-buffered saline (PBS) and supplemented with fresh
DMEM containing 10% FBS. Cells were collected at 36 to 48 h posttransfection,
or at 24 h posttransfection cells were serum starved for a further 24 h, and
processed for either immunoprecipitation or immunofluorescence assays.
Plasmid constructs. pBluescript II KS (Stratagene, La Jolla, Calif.) constructs
encoding wild-type 48- and 45-kDa TCPTP cDNAs and the wild-type and mutant
PTP1B construct in pMT2 have been described elsewhere (16, 53). Site-directed
mutagenesis of the 45- and the 48-kDa TCPTP cDNAs to generate D182A
mutants in pMT2 was accomplished by using the U-labeled template method of
Kunkel (31) and a Bio-Rad (Hercules, Calif.) Mutagene kit. TCPTP 45-kDa
pCG constructs were generated by PCR using the cloned Pfu DNA polymerase
(Stratagene). The TCPTP/1B chimera construct, encoding the TCPTP catalytic
domain (residues 1 to 321) and the C-terminal 35 residues of PTP1B, was
generated by PCR and subcloned into the XbaI/EcoRI digested wild-type and
mutant 45-kDa TCPTP pMT2 constructs. The c-Src Y527F-pJ3V construct was
generated by subcloning the c-Src Y527F pMIKneo fragment into pBluescript
and then further subcloning the HindIII/KpnI fragment from this into pJ3V (39).
DNA encoding GST-tagged Shc (amino acids 17 to 473) and the various Shc
mutants were generated by subcloning Shc into the pEBG vector (52). Y239F,
Y240F, and Y317F mutants were generated by using primers that carry the
desired mutations in a PCR-based mutagenesis as described previously (32). The
structures of the recombinant plasmids generated were confirmed by restriction
endonuclease analysis and sequencing.
Immunoprecipitation and immunoblotting. Two 10-cm-diameter dishes of
cells transfected with the wild-type and mutant TCPTP- or PTP1B-pMT2 con-
structs were washed three times with ice-cold PBS and lysed in 0.9 ml of IP
(immunoprecipitation) lysis buffer (50 mM Tris-HCl [pH 7.5], 1% [wt/vol] Triton
X-100, 200 mM NaCl, 5 mM iodoacetic acid, 5 mM NaF, leupeptin [5 mg/ml],
aprotinin [5 mg/ml], pepstatin A [1 mg/ml], 1 mM benzamidine, 2 mM phenyl-
methylsulfonyl fluoride) on ice. Cell lysates were precleared with 0.1 ml of IgG
Sorb (The Enzyme Center, Malden, Mass.) for 30 min at 4°C. Precleared lysates
were subsequently centrifuged (12,000 3 g for 5 min at 4°C), and TCPTP or
PTP1B was immunoprecipitated with 15 mg of monoclonal anti-TCPTP antibody
CF4 or 10 ml of anti-PTP1B FG6 ascites prebound to protein A-Sepharose
CL-4B (Pharmacia, Uppsala, Sweden). Where indicated, TCPTP and the
TCPTP/1B chimera were immunoprecipitated for 1 to 2 h at 4°C with 15 ml of
rabbit polyclonal antiserum 6228 to TCPTP. The precipitates were collected by
centrifugation (12,000 3 g, 1 min) and washed once with ice-cold IP lysis buffer,
four times with ice-cold IP lysis buffer without iodoacetic acid, and once with
ice-cold 50 mM Tris-HCl (pH 7.5). Immune complexes were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
Immobilon (Millipore, Bedford, Mass.), probed with monoclonal anti-pTyr an-
tibody G98 (subtype IgM) at a 1:1,000 dilution of ascites, and detected with
peroxidase-conjugated goat anti-IgM (Cappel, Durham, N.C.) at a dilution of
1:4,000. Anti-TCPTP CF4, anti-PTP1B FG6, and anti-pTyr G98 antibodies were
diluted in 20 mM Tris-HCl (pH 7.5)–500 mM NaCl–0.05% Tween 20–5% (wt/
vol) nonfat dry milk. All other antibodies were diluted in 20 mM Tris-HCl (pH
7.5)–150 mM NaCl–0.1% Tween 20–5% nonfat dry milk. Monoclonal anti-
TCPTP antibody CF4 was used at 1 mg/ml, polyclonal anti-Shc antibody (Trans-
duction Laboratories, Lexington, Ky.) was used at 1 mg/ml, monoclonal anti-
Grb2 antibody (Transduction Laboratories) was used at 0.25 mg/ml, rabbit anti-
EGFR polyclonal antiserum 1964 was used at a dilution of 1:2,000, and
monoclonal anti-EGFR antibody EGFR1 (BIOMOL Research Laboratories
Inc., Plymouth Meeting, Pa.) was used at 1 mg/ml. These antibodies were de-
tected with peroxidase-conjugated donkey anti-rabbit or sheep anti-mouse anti-
bodies (Amersham Life Science, Cleveland, Ohio) at a dilution of 1:4,000. All
blots were developed by using enhanced chemiluminescence (Amersham).
p42Erk2 kinase assays. COS1 cells, in 10-cm-diameter dishes, were transfected
with 2 mg of HA-tagged p42Erk2 pJ3H plasmid and either 15 mg of the pMT2
plasmid or 15 mg of the 45-kDa TCPTP or 45-kDa TCPTP D182A pMT2
plasmid. Cells were serum starved overnight, either left unstimulated or stimu-
lated with 100 ng of EGF per ml for 20 min, and processed for p42Erk2 kinase
assays. HA-tagged p42Erk2 was immunoprecipitated with anti-HA antibody
12CA5 (5 ml of ascites per 10-cm-diameter dish of cells) for 90 min at 4°C, and
p42Erk2 kinase activity was measured by using myelin basic protein as substrate
as previously described (3). Anti-HA immune complexes from these reactions
were resolved by SDS-PAGE, immunoblotted with anti-HA antibodies, and
quantitated by densitometry in order to normalize for HA-Erk2 activity.
Immunofluorescence. COS1 cells were seeded onto glass coverslips, trans-
fected, and processed at 36 to 48 h posttransfection. Cells were then washed
three times with PBS, fixed for 15 min at room temperature with 3.2% parafor-
maldehyde in PBS, washed twice with PBS and once with 150 mM glycine in PBS,
and incubated with 150 mM glycine in PBS for 10 min. Following two PBS
washes, cells were permeabilized with 0.2% (wt/vol) Triton X-100 in PBS (PBST)
for 2 min and blocked with 5% normal goat serum in PBST for 30 min. Mono-
clonal anti-TCPTP antibody CF4 or polyclonal affinity-purified anti-TCPTP an-
tibody 6228 was applied at 0.7 or 0.8 mg/ml, respectively. Polyclonal anti-EGFR
serum 1964 (directed to the intracellular EGFR domain) was applied at a
dilution of 1:500. Monoclonal anti-protein disulfide isomerase (PDI; StressGen
Biotechnologies Corp., Victoria, British Columbia, Canada) was applied at 10
mg/ml. Anti-HA ascites (12CA5), anti-Myc ascites (9E10), and anti-Src ascites
(D710) were applied at a dilution of 1:100. Anti-pTyr-specific ascites G98 (sub-
type IgM) was applied at a dilution of 1:1,000. Antibodies were diluted in PBST
containing 0.5% normal goat serum and incubated for 1 h at room temperature.
Cells were washed three times with PBST, and fluorescein isothiocyanate
(FITC)-conjugated (goat anti-rabbit, goat anti-mouse, or goat anti-mouse IgM)
and Texas red-conjugated (sheep anti-mouse or goat anti-rabbit) antibodies
(Cappel) were applied for 30 min at a dilution of 1:200 in PBST. Cells were
washed twice with PBST and twice with PBS and incubated for 1 min with
Hoechst 33258 (Molecular Probes, Eugene, Oreg.) diluted in PBS to a concen-
tration of 2.5 mg/ml. Cells were then washed three times with PBS, and coverslips
were mounted in mounting medium (6.6 mM sodium bicarbonate, 0.57 mM
anhydrous sodium carbonate, 0.95 mg of p-phenylenediamine [Aldrich, Milwau-
kee, Wis.] per ml, 80.9% [vol/vol] glycerol [Polysciences Inc., Warrington, Pa.]
[final pH of 8.0]). Immunofluorescence was visualized on a Nikon Microphot-
FXA microscope.
GST precipitations. For GST-Grb2 precipitations, COS1 cells grown in 10-
cm-diameter dishes were cotransfected with 15 mg of 45-kDa TCPTP pMT2
plasmid, 45-kDa TCPTP D182A pMT2 plasmid, or pMT2 alone and 5 mg of
GST-Grb2 pMT3 plasmid. Cells were serum starved and either left unstimulated
or stimulated with EGF (100 ng/ml) for 20 min. Cells were then lysed in 0.9 ml
of IP lysis buffer, lysates were precleared with 0.1 ml of IgG Sorb and centrifuged
(12,000 3 g for 5 min at 4°C), and dithiothreitol (DTT) was added to superna-
tants to 2 mM. GST-Grb2 was precipitated with glutathione-Sepharose 4B (Phar-
macia Biotech, Piscataway, N.J.) for 60 min at 4°C, precipitates were washed with
IP lysis buffer containing 2 mM DTT and then split into two, and proteins were
resolved by SDS-PAGE and immunoblotted with either polyclonal anti-Shc
antibody or a monoclonal anti-Grb2 antibody. The TCPTP expression levels in
lysates were analyzed by immunoblotting with the anti-TCPTP CF4 antibody.
For GST-Shc precipitations, COS1 cells grown in 10-cm-diameter dishes were
transfected with 5 mg of either vector, wild-type Shc, or tyrosine-to-phenylalanine
Shc mutants (Y317F, Y239F, Y239F/Y240F, and Y317F/Y239F/Y240F) in
pEBG. Cells were serum starved, either left unstimulated or stimulated with
EGF (100 ng/ml) for 20 min, then lysed in 0.9 ml of IP lysis buffer containing 2
mM vanadate (without iodoacetic acid), and centrifuged at 12,000 3 g for 20 min
at 4°C. DTT was added to the supernatants to 1 mM, and GST-Shc was precip-
itated with glutathione-Sepharose 4B for 90 min at 4°C. Precipitates were washed
with the same lysis buffer as specified above containing 1 mM DTT and split into
two, and proteins were resolved by SDS-PAGE and immunoblotted with anti-
pTyr G98 antibody, anti-Shc antibody, or anti-Grb2 antibody.














45-kDa TCPTP D182A/GST-Shc association assays. COS1 cells grown in
10-cm-diameter dishes were cotransfected with 5 mg of the 45-kDa TCPTP
D182A pMT2 plasmid and either 5 mg of pEBG vector control, wild-type Shc, or
tyrosine-to-phenylalanine Shc mutants (Y317F, Y239F, Y239F/Y240F, and
Y317F/Y239F/Y240F) in pEBG. At 24 h posttransfection, cells were serum
starved for 24 h and either left unstimulated or stimulated with EGF (100 ng/ml)
for 20 min. Cells were then lysed in 2.0 ml of IP lysis buffer, and lysates were
precleared with IgG Sorb. Precleared lysates were centrifuged (5,000 3 g for 5
min at 4°C), and TCPTP was immunoprecipitated with antibody CF4. Precipi-
tates were resolved by SDS-PAGE and immunoblotted with anti-Shc antibody or
anti-TCPTP antibody CF4. The expression levels of the GST-Shc proteins were
analyzed by immunoblotting with Shc antibodies.
RESULTS
Identification of substrates of TCPTP and PTP1B. In this
study, we have used a substrate-trapping approach (16, 19) to
compare the substrate recognition of the alternatively spliced
and differentially localized TC48 and TC45 proteins. In addi-
tion, we have compared the substrate specificity of TC48 and
the highly related enzyme PTP1B (74% sequence identity
within the catalytic domain), both of which are targeted to the
cytoplasmic face of membranes of the ER (17, 35).
COS1 cells transiently overexpressing wild-type or substrate-
trapping mutant forms of either TCPTP or PTP1B were serum
starved and stimulated with EGF. Stimulation of COS1 cells
with EGF resulted in a dramatic increase in the number of
pTyr proteins (Fig. 1A). The expressed PTPs were precipitated
with specific monoclonal antibodies to TCPTP and PTP1B,
and the associated proteins were visualized by anti-pTyr im-
munoblotting (Fig. 1B, upper panel). We found that whereas
no pTyr proteins were present in wild-type TCPTP or PTP1B
immunoprecipitates, a number of pTyr proteins were precipi-
tated by using the substrate-trapping mutants (Fig. 1B, upper
panel). Wild-type and substrate-trapping mutants of TCPTP
(D182A) and PTP1B (D181A) were expressed and precipi-
tated at similar levels (Fig. 1B, lower panel). Despite the ex-
tensive similarity between TCPTP and PTP1B catalytic do-
mains, their respective substrate-trapping mutants precipitated
distinct patterns of pTyr proteins (Fig. 1B). Although the
TC48-D182A, TC45-D182A, and PTP1B-D181A mutants pre-
cipitated a 180-kDa pTyr protein (p180) in common, differ-
ences were observed in the lower-molecular-mass pTyr pro-
teins present in the complexes. Only the PTP1B-D181A
mutant precipitated a 60-kDa pTyr protein (p60). In addition,
the TC45-D182A mutant precipitated pTyr proteins of 50, 57,
and 64 kDa (p50, p57, and p64) that were not precipitated by
the TC48-D182A or PTP1B-D181A mutant (Fig. 1B). The
;86-kDa band present in wild-type PTP1B and PTP1B-D181A
mutant immunoprecipitates is IgM derived from the anti-
PTP1B FG6 ascites used for precipitation and recognized by
the anti-IgM peroxidase-conjugated secondary antibody.
Although the treatment of COS1 cells with EGF stimulated
the tyrosine phosphorylation of a large number of proteins
(Fig. 1A), the TCPTP and PTP1B substrate-trapping mutants
precipitated only a small subset of these potential substrates.
Furthermore, the substrate-trapping mutant PTPs did not rec-
ognize only the most highly phosphorylated substrates but ap-
peared to bind selectively to pTyr proteins which were minor
components of the pTyr pattern in cells lysates (p60 for
PTP1B-D181A; p50, p57, and p64 for the TC45-D182A mu-
tant) (Fig. 1A and B, upper panel). These results indicate that
TCPTP and PTP1B have a restricted substrate specificity in
vivo and, importantly, that they exhibit differences in substrate
specificity. The fact that TC48-D182A and TC45-D182A mu-
tants, which have the same catalytic domain, recognized dis-
tinct substrates indicates that subcellular localization may play
a critical role in dictating TCPTP substrate recognition in vivo.
Differential recognition of p60 by PTP1B and TC48 is due to
differences in intrinsic substrate specificity. Considering that
PTP1B and TC48 both localize to the ER and show 74%
identity within their catalytic domains (65% identity overall)
(4, 9, 13), one may have predicted that the 60-kDa PTP1B
substrate would also be recognized by the TC48-D182A sub-
strate-trapping mutant. To examine whether the apparent
specificity of PTP1B for the 60-kDa substrate was attributable
to differences in inherent substrate specificity, or to possible
differences in the ER microenvironments in which PTP1B and
TCPTP reside, we sought to relocalize the TC48-D182A mu-
tant to the precise location of PTP1B in the ER. We generated
a TCPTP/PTP1B chimera comprising the TCPTP catalytic do-
main (residues 1 to 320; TC37) and the extreme C-terminal 35
residues of PTP1B which are necessary and sufficient for ER
localization (17) (Fig. 2A). The wild-type (TC37/1B) and
D182A (TC37D/1B) chimeras were expressed transiently in
COS1 cells, and the ability of the TC37D/1B chimera to asso-
ciate with pTyr proteins was investigated. Although the
TC37D/1B chimera was efficiently targeted to the ER by the
C-terminal 35 residues of PTP1B, as assessed by its colocaliza-
tion with the ER marker PDI (data not shown), it did not
precipitate the PTP1B 60-kDa substrate (Fig. 2). Similar levels
of TCPTP, PTP1B, and the chimeric proteins were expressed
and precipitated (data not shown). These results indicate that
the selectivity of PTP1B for the 60-kDa substrate is most likely
attributable to inherent substrate specificity and not to differ-
ences in the ER microenvironments of TCPTP and PTP1B. A
nonspecific band of ;70 kDa is present in all immunoprecipi-
FIG. 1. Precipitation of TCPTP and PTP1B substrates by using the Asp3Ala
trapping mutants. (A) COS1 cells were serum starved and stimulated with 100 ng
of EGF per ml for 15 min at 37°C. Cells were lysed in 33 Laemmli sample buffer,
and proteins were resolved by SDS-PAGE (10% gel) and immunoblotted with
the anti-pTyr antibody G98. Molecular size markers (prestained from Sigma; lot
125H9408) are indicated in kilodaltons on the left. (B) COS1 cells transiently
transfected with either the 48-kDa (TC48) or 45-kDa (TC45) TCPTP wild-type
construct or D182A mutants (TC48D and TC45D) or with the PTP1B (1B)
wild-type construct or D181A mutant (1BD) were serum starved and stimulated
with EGF (100 ng/ml) for 15 min at 37°C. Cells were then lysed, and TCPTP or
PTP1B immunoprecipitates were resolved by SDS-PAGE (10% gel) and immu-
noblotted with the anti-pTyr antibody G98 (upper panel) or with a TCPTP-
specific (CF4) or PTP1B-specific (FG6) antibody (lower panel). The major pTyr
proteins coprecipitating with TC48D (p180), TC45D (p180, p64, p57, and p50),
or 1BD (p180 and p60) are indicated by arrows on the right, and positions of
molecular size standards are shown on the left.














tates, including the vector-alone control (data not shown), and
therefore is not a substrate of TCPTP or PTP1B. The reverse
chimera, containing the PTP1B catalytic domain (residues 1 to
321) and the TCPTP C-terminal domain (residues 320 to 415),
was unstable and proteolyzed (data not shown). The results
indicate that the PTP1B and TC48 exhibit differences in spec-
ificity despite their similar subcellular localization and high
degree of sequence similarity. Whether the specificity of
PTP1B for the 60-kDa substrate is attributable solely to its
catalytic domain or also involves sequences from the noncata-
lytic C-terminal segment remains to be established.
Criteria for classification of pTyr proteins as PTP sub-
strates. The 180-kDa substrate recognized by the TC45, TC48,
and PTP1B substrate-trapping mutants was identified by im-
munoblot analysis as the EGFR (Fig. 3A). The following ob-
servations support the classification of EGFR as a substrate for
these PTPs. First, the inclusion of vanadate, a PTP inhibitor
that covalently modifies the invariant, essential nucleophilic
cysteine residue at the active site (14, 28), disrupted formation
of complexes between the substrate-trapping mutant PTPs and
the pTyr EGFR (Fig. 4A). Similarly, addition of vanadate
disrupted all of the mutant PTP-pTyr protein complexes ob-
served in Fig. 1 (data not shown). The findings that wild-type
PTPs did not precipitate the pTyr proteins or the dephospho-
rylated form of the EGFR and that vanadate disrupted the
association of pTyr proteins with the substrate-trapping mu-
tant PTPs indicate that the pTyr proteins that coprecipitated
with the mutant enzymes are likely to be PTP substrates that
interact exclusively through the active site. Second, comparison
of the state of tyrosine phosphorylation of the EGFR in cell
lysates following expression of either wild-type or substrate-
trapping mutant PTPs (Fig. 4B) revealed that in comparison to
cells expressing the vector control, the EGFR is dephosphory-
lated by the wild-type PTPs but protected from dephosphory-
lation by the substrate-trapping mutants, consistent with a di-
rect recognition of the EGFR as substrate by these PTPs.
FIG. 2. PTP1B, but not TC48, exhibits inherent specificity for pTyr protein p60. (A) Schematic representation of PTP1B (1B), the 48-kDa TCPTP (TC48), and the
TC37/1B chimera. (B) COS1 cells transiently transfected with the constructs indicated at the top were serum starved and stimulated with EGF for 15 min. Cells were
then lysed, and immunoprecipitates were generated with the indicated antibodies. The epitope for anti-TCPTP CF4 is within residues 349 to 415 of TC48, whereas that
of the anti-TCPTP 6228 epitope is within TCPTP residues 1 to 320. Immunoprecipitates were resolved by SDS-PAGE (10% gel) and immunoblotted with the anti-pTyr
antibody G98. p180 and p60 substrates are indicated by arrows on the left, and molecular size standards (in kilodaltons) are on the right. The heavy ;86-kDa band
present in both wild-type and mutant 1B immunoprecipitates is IgM derived from the precipitating antibody (anti-PTP1B FG6 ascites).
FIG. 3. Interaction of substrate-trapping mutant TCPTP and pTyr EGFR
and -p52Shc. (A) TCPTP (TC48 and TC45) or PTP1B (1B) or their respective
Asp3Ala mutants (TC48D, TC45D, and 1BD) were immunoprecipitated, re-
solved by SDS-PAGE, and immunoblotted with either the anti-pTyr antibody
G98 (upper panel) or anti-EGFR rabbit polyclonal antiserum 1964 (lower pan-
el). (B) TCPTP and PTP1B wild-type or D182A immunoprecipitates were re-
solved by SDS-PAGE and immunoblotted with either anti-pTyr antibody G98
(upper panel) or anti-Shc antibody (lower panel). Panels A and B show different
regions of different gels.














The TC48-D182A mutant traps the EGFR at the ER. Previ-
ously, we have reported that the PTP1B-D181A mutant retains
and accumulates the endogenous EGFR in an intracellular
complex (16). To investigate whether the TC48-D182A mutant
also results in the accumulation of EGFR, we examined the
location of endogenous EGFR in randomly growing COS1
cells transfected with either TC48 or the TC48-D182A mutant.
TC48 and TC48-D182A exhibited a reticular staining pattern
in COS1 cells (Fig. 5) which colocalized with the ER marker
PDI (data not shown). In contrast, the endogenous EGFR
exhibited a uniform and diffuse staining in cells overexpressing
TC48 (Fig. 5, upper right). However, in cells expressing the
TC48-D182A substrate-trapping mutant, the endogenous
EGFR displayed intense punctuate staining (Fig. 5, lower
right) which colocalized with foci of anti-TCPTP staining (Fig.
5, lower left). Similar results were obtained for TC48-D182A in
cells following serum starvation with or without EGF stimula-
tion (data not shown). These results demonstrate that expres-
sion of the TC48-D182A substrate-trapping mutant modifies
localization of EGFR, likely through a physical association
which retains and accumulates the EGFR in the ER. These
data illustrate the important point that the complex was
formed in the intact cell and did not arise from an event that
occurred postlysis.
EGFR and p52Shc are specific substrates of TC45. The 180-
kDa pTyr protein precipitated by the TC45-D182A mutant was
identified by immunoblot analysis as the EGFR (Fig. 3A),
whereas the 57-kDa pTyr protein was identified as the adaptor
protein p52Shc (Fig. 3B). Neither p52Shc nor EGFR was
present in immunoprecipitates of wild-type TCPTP or PTP1B.
We used a specific monoclonal antibody that recognizes all
isoforms of Shc in COS1 cells (p46Shc, p52Shc, and p66Shc) but
did not detect cross-reactivity with the 50- or 64-kDa pTyr
protein precipitated by the TC45-D182A mutant (data not
shown). p52Shc was also detected in immunoprecipitates of the
TC48-D182A and PTP1B-D181A mutants (Fig. 3B); however,
it was not tyrosine phosphorylated, indicating that p52Shc is not
a substrate for either TC48 or PTP1B (Fig. 1B, 2, and 3B). Shc
is known to associate directly with pTyr EGFR via its PTB and
SH2 domains (1, 2); however, it is not tyrosine phosphorylated
when cell lysates are prepared in the absence of the PTP
inhibitor vanadate. In these experiments, the cells were lysed in
the absence of vanadate; therefore, it is likely that the presence
of unphosphorylated p52Shc in TC48-D182A and PTP1B-
D181A immunoprecipitates is due to its direct association with
the pTyr EGFR. In addition, although equal amounts of pTyr
EGFR were precipitated by the TC45-D182A and TC48-
D182A mutants (Fig. 3A), more p52Shc protein associated with
the TC45-D182A mutant than the TC48-D182A mutant (Fig.
3B), presumably reflecting an EGFR-independent interaction
between pTyr p52Shc and TC45-D182A.
The TC45-D182A mutant undergoes a change in localization
from the nucleus to the cytoplasm following EGF stimulation.
At first, the ability of the TC45-D182A mutant to associate
with EGFR and p52Shc appeared to be enigmatic. Numerous
studies including our own (35, 53, 54) have reported exclusive
nuclear localization of TC45, whereas EGFR and Shc are
known to reside outside the nucleus. We postulated that the
TC45-D182A mutant may relocalize to the cytoplasm, thereby
allowing its association with pTyr EGFR and Shc. To address
this possibility, we correlated the precipitation of pTyr proteins
with the localization of the TC45-D182A mutant in cells stim-
ulated with IFN-a and -g or EGF. We used IFN as a control
because it stimulates the JAK/STAT pathway and results in
translocation of tyrosyl-phosphorylated STATs to the nucleus
(reviewed in reference 29). We found that in serum-starved
cells or in cells stimulated with IFN, there was no detectable
association of the TC45-D182A mutant with pTyr proteins
(Fig. 6A). Notably, the TC45-D182A mutant did not precipi-
tate the IFN-inducible, ;86-kDa pTyr protein (Fig. 6A) which
was present in the lysates (Fig. 6B) and was identified by
immunoblot analysis as STAT1 (data not shown). In serum-
starved cells and in IFN-stimulated cells, the TC45-D182A
mutant was predominantly nuclear (Fig. 6C). In marked con-
trast, stimulation of COS1 cells overexpressing the TC45-
D182A mutant with EGF resulted in the precipitation of the
pTyr proteins described above (Fig. 6A), which correlated with
a dramatic increase of TCPTP in the cytoplasm (Fig. 6C). This
change in localization was transient; it occurred rapidly, within
5 min of EGF stimulation, reached a maximum within 15 to 30
min in ;90% of cells overexpressing the TC45-D182A protein,
and returned to the nucleus within 6 h (data not shown).
Considering that the change in localization occurred in such a
short time period, it is unlikely to represent de novo synthesis
of the TC45-D182A protein.
We also observed that the TC45-D182A mutant accumu-
lated in the cytoplasm of 30 to 50% of randomly growing cells
(data not shown), indicating that a signal to trigger this event
exists in randomly growing cells. Although an EGF-dependent
change in localization of the TC45-D182A mutant was readily
observed, a change in localization of the wild-type TC45 en-
zyme could not be detected by immunofluorescence. There-
fore, heterokaryon assays, which are used to characterize pro-
teins that are retained in the nucleus or that undergo
nucleocytoplasmic transport (41, 44), were performed as an
independent confirmation of the ability of TC45 to exit the
nucleus. Randomly growing HeLa cells overexpressing TC45
and randomly growing, untransfected NIH 3T3 cells were
FIG. 4. The EGFR is a substrate of TCPTP. (A) COS1 cells transiently
transfected with either the wild-type 48-kDa (TC48) or 45-kDa (TC45) TCPTP
or D182A mutants (TC48D and TC45D) or with the wild-type PTP1B (1B) or
D181A mutant (1BD) were serum starved and stimulated with EGF (100 ng/ml)
for 15 min at 37°C. Cells were lysed in the presence or absence of 2 mM
vanadate, and TCPTP or PTP1B immunoprecipitates were resolved by SDS-
PAGE (10% gel) and immunoblotted with anti-pTyr antibody G98. (B) COS1
cells transiently transfected with indicated plasmid constructs were serum starved
and stimulated with EGF (100 ng/ml) for 15 min at 37°C. Cells were lysed in IP
lysis buffer, lysates were precleared with IgG Sorb, and supernatants were re-
solved by SDS-PAGE (10% gel) and immunoblotted with either the anti-pTyr
antibody G98 (upper panel) or anti-EGFR rabbit polyclonal antiserum 1964
(lower panel).














fused to form heterokaryons in which human and mouse nuclei
share a common cytoplasm. The overexpressed TCPTP was
detected in both HeLa and 3T3 nuclei but not in the cytoplasm
of the heterokaryons (data not shown). Since heterokaryons
were generated in the presence of cycloheximide, the recovery
of TC45 in 3T3 nuclei reflects shuttling of the PTP between the
nucleus and cytoplasm rather than de novo synthesis. These
results demonstrate that TC45 is not restricted to the nucleus,
but that it can exit and therefore attain access to cytoplasmi-
cally localized substrates.
The change in TC45-D182A localization requires EGFR ty-
rosine kinase activity. To characterize further the cytoplasmic
translocation of TC45-D182A in response to EGF, we deter-
mined whether EGFR activation was required for this event to
occur. COS1 cells overexpressing TC45-D182A were pre-
treated for 90 min with the protein tyrosine kinase (PTK)
inhibitor DAPH, which at low concentrations (#10 mM) is
highly selective for the EGFR (5), and the effect of EGF on
TC45-D182A localization was assessed (Fig. 7). In serum-
starved COS1 cells, 10 mM DAPH significantly inhibited the
EGF-induced EGFR autophosphorylation and the cytoplasmic
translocation of the TC45-D182A mutant (Fig. 7). These re-
sults suggest that EGFR PTK activity is essential for the EGF-
induced change in localization of TC45-D182A.
In addition, we investigated the influence of downstream
targets of the EGFR on TC45-D182A localization. Pretreat-
ment of TC45-D182A-expressing cells with rapamycin and
wortmannin, which inhibit the activation of the 70-kDa S6
kinase (10) and phosphatidylinositol-3-kinase activities, re-
spectively (23, 60), did not prevent the EGF-induced change in
localization (data not shown). Coexpression of TC45-D182A
with constitutively active forms of Ras (RasV12) and Raf (Raf-
CAAX), which induced mitogen-activated protein kinase
(MAPK) activation, did not stimulate cytoplasmic transloca-
tion in randomly growing cells in which the TC45-D182A pro-
tein was nuclear (data not shown). Consistent with previous
reports (37, 59), overexpression of a constitutively active form
of c-Src, Src Y527F, dramatically increased the total cellular
pTyr content (Fig. 8B and C) and resulted in the phosphory-
lation of Shc on Y239/240 and Y317, a TCPTP substrate (data
not shown). However, we found that coexpression of Src
Y527F did not significantly alter localization of the TC45-D182
in serum-starved cells (Fig. 8A). These results suggest that the
change in TCPTP localization may result from a specific sig-
naling event emanating from the EGFR PTK and is not due
simply to hyperactivation of signaling pathways or hyperphos-
phorylation of proteins on tyrosine in general.
TC45 modulates the association of p52Shc with Grb2 but not
the activation of p42Erk2. The identification of EGFR and
p52Shc as potential substrates of TC45 suggests that the PTP
may modulate the function of these molecules in EGFR sig-
naling. First, we examined the effect of TCPTP on the activa-
tion of the MAPK p42Erk2 in response to EGF (Fig. 9A). COS1
cells were cotransfected with HA-tagged p42Erk2 and either the
FIG. 5. Colocalization of the TC48-D182A substrate-trapping mutant and endogenous EGFRs. COS1 cells seeded on glass coverslips were transfected with
wild-type TC48 (upper half) or D182A mutant (lower half). At 36 h posttransfection, cells were fixed with paraformaldehyde and processed for immunofluorescence
as described in Materials and Methods. Cells were incubated with mouse monoclonal TCPTP CF4 antibody and anti-EGFR rabbit polyclonal antiserum 1964.
Overexpressed TC48 (left) and endogenous EGFR (right) were visualized with FITC-conjugated goat anti-mouse and Texas red-conjugated goat anti-rabbit antibodies,
respectively. Original magnification, 3600.














wild-type TC45 or the TC45-D182A mutant. The effects of
TCPTP on the EGF-induced p42Erk2 activity were ascertained
at EGF concentrations of 1 ng/ml, 10 ng/ml (data not shown),
and 100 ng/ml (Fig. 9A) and at 2 min (data not shown) and 15
min (Fig. 9A) after the addition of growth factor. Although the
TC45-D182A mutant precipitated pTyr EGFR and p52Shc un-
der these conditions, it failed to modulate basal or EGF-in-
ducible p42Erk2 activity (Fig. 9A). These results indicate that
FIG. 6. EGF-dependent change in localization of TC45-D182A and associ-
ation with pTyr substrates. COS1 cells transfected with the 45-kDa TCPTP wild
type (TC45) or D182A mutant (TC45D) were serum starved and either left
unstimulated (2) or stimulated with EGF (100 ng/ml) or IFN (10 ng of IFN-g
and 1,000 U of IFN-a per ml) for 15 min. (A) Cells were lysed, and overex-
pressed TCPTP was immunoprecipitated, resolved by SDS-PAGE (10% gel),
and immunoblotted with the anti-pTyr antibody G98. The major pTyr-containing
proteins coprecipitating with TC45D (p180, p64, p57, and p50) are indicated by
arrows on the left. Molecular size standards (in kilodaltons) are shown on the
right. (B) COS1 cells were serum starved and stimulated with either EGF or IFN
as described above. Cells were lysed in 33 Laemmli sample buffer, and proteins
were resolved by SDS-PAGE (10% gel) and immunoblotted with the anti-pTyr
antibody G98. (C) Cells were processed for immunofluorescence by using the
anti-TCPTP CF4 antibody. Original magnification, 3600.














the association of the TC45-D182A mutant with the EGFR,
p52Shc, p50, and p64 does not modulate p42Erk2 activation in
response to EGF.
Since the results of this study indicate that p52Shc is a sub-
strate of TC45, we formed the hypothesis that the phosphatase
may affect the association of Shc with Grb2. COS1 cells were
cotransfected with GST-Grb2 and either the wild-type TC45 or
the TC45-D182A mutant. GST-Grb2 was precipitated from
both serum-starved and EGF-stimulated cells, and the effect of
TCPTP on the association with p52Shc was assessed by immu-
noblotting. We found that overexpression of the wild-type
TC45, and to a lesser extent the TC45-D182A mutant, im-
paired EGF-induced association of p52Shc with Grb2 (Fig. 9B).
That the TC45-D182A inhibition of GST-Grb2/Shc association
was less efficient than that of the wild-type enzyme can most
likely be attributed to substrate trapping by the D182A mutant
being less efficient than dephosphorylation in vivo. These re-
sults suggest that TCPTP may serve to modulate a p52Shc/
Grb2-induced signaling pathway that is independent of EGF-
induced p42Erk2 activation.
The TC45-D182A mutant recognizes specific sites of ty-
rosine phosphorylation on Shc. Recent studies have demon-
strated that Shc is phosphorylated on tyrosines 239 and 240 as
well as tyrosine 317 following EGFR activation (21, 22, 24, 59).
Both the Y317 and Y239 sites are capable of binding Grb2 (22,
24, 59). The presence of multiple sites of tyrosine phosphory-
lation on Shc suggests that it may participate in more than one
signaling pathway. Indeed, the Shc phosphorylation site mu-
tant Y317F can inhibit the EGF-induced stimulation of
MAPK, whereas the Y239F/Y240F mutant does not (22), im-
plicating Y317 and not Y239/Y240 in activation of the MAPK
pathway. We tested whether TC45 recognizes Shc Y239/Y240
specifically and thus can exert an effect on Shc/Grb2 associa-
tion without affecting p42Erk2 activation.
First, we examined both the phosphorylation state of Shc
FIG. 7. The EGFR-specific PTK inhibitor DAPH inhibits the EGF-depen-
dent change in localization of the TC45-D182A substrate-trapping mutant.
COS1 cells grown on coverslips and transfected with mutant TC45-D182A were
serum starved and preincubated with 0, 5, 10, or 50 mM DAPH, the specific
inhibitor of the EGFR PTK, for 90 min at 37°C and 5% CO2. Cells were either
left unstimulated (2) or stimulated with EGF (100 ng/ml) for 15 min. Cells were
subsequently either fixed with paraformaldehyde and processed for immunoflu-
orescence by using the anti-TCPTP CF4 antibody or lysed in 33 Laemmli sample
buffer, and proteins were resolved by SDS-PAGE (10% gel). Resolved proteins
were then immunoblotted with the anti-pTyr antibody G98 or the monoclonal
anti-EGFR antibody EGFR1. The top panel shows representative fields from
immunofluorescence studies at a magnification of 3200.














and the association of endogenous Grb2 following EGF stim-
ulation (Fig. 10A). COS1 cells were transfected with wild-type
or various tyrosine-to-phenylalanine mutants of a GST-Shc
fusion protein (Y317F, Y239F, Y239/240F, and Y317F/Y239F/
Y240F), and the state of Shc phosphorylation in GST-Shc
precipitates was determined by anti-pTyr immunoblotting.
Consistent with previous studies (22, 59), we observed phos-
phorylation of Shc in response to EGF not only on tyrosine 317
but also on tyrosines 239 and 240 (Fig. 10A). The Y3F mu-
tations in Shc did not alter the ability of the GST-Shc mutants
to associate with the EGFR (data not shown). Therefore, dif-
ferential phosphorylation of the GST-Shc mutants was not due
to inappropriate localization. When the same GST-Shc precip-
itates were immunoblotted with antibodies to Grb2, we ob-
served that although the wild-type GST-Shc and the GST-Shc
Y317F mutant associated with endogenous Grb2 to similar
levels, Grb2 binding was significantly reduced in GST-Shc
Y239F and Y239F/240F precipitates (Fig. 10A). These results
indicate that in COS1 cells, tyrosines 239 and 240 of p52Shc are
FIG. 8. Expression of Src Y527F does not induce the change in TC45-D182A
localization. COS1 cells seeded on glass coverslips in 60-mm-diameter dishes
were cotransfected with either 5 mg of TC45-D182A plasmid and 1 mg of Src
Y527F plasmid or transfected with 1 mg of Src Y527F plasmid alone. Transfected
cells were serum starved and processed for immunofluorescence by using the
TCPTP antibody CF4. (A) Cells transfected with TC45-D182A and Src Y527F
were incubated with rabbit polyclonal TCPTP antibody 6228 and monoclonal
anti-Src antibody D710. Overexpressed Src Y527F was visualized with Texas
red-conjugated sheep anti-mouse antibodies, and TCPTP was visualized with
FITC-conjugated goat anti-rabbit antibodies. (B) Cells transfected with empty
vector (left) or with Src Y527F plasmid (right) were incubated with the pTyr
antibody G98. pTyr was visualized with FITC-conjugated goat anti-mouse IgM.
(C) COS1 cells transfected with empty vector or with Src Y527F plasmid were
serum starved and either left unstimulated (2) or stimulated with EGF for 15
min. Cells were then collected in 33 Laemmli sample buffer, and proteins were
resolved by SDS-PAGE (10% gel) and immunoblotted with anti-pTyr antibody
G98. Molecular size standards (in kilodaltons) are shown on the right.














phosphorylated and that tyrosine 239 is a major Grb2 binding
site (Fig. 10A). Taken together with the ability of TCPTP to
inhibit the association of Grb2 with p52Shc without affecting
p42Erk2 activity, these results strongly suggest that TC45 spe-
cifically recognizes Shc phosphorylated on Y239 but not Y317.
To test this hypothesis, we assessed the ability of TC45-
D182A to associate, in an EGF-dependent manner, with Shc
mutated in the various phosphorylation sites (Fig. 10B). COS1
cells were cotransfected with the TC45-D182A mutant and the
wild-type or mutant Y3F GST-Shc constructs. The amount of
GST-Shc in TC45-D182A precipitates was determined follow-
ing EGF stimulation by immunoblotting with anti-Shc antibod-
ies. GST-Shc associated with TC45 in a nonspecific manner
which was independent of tyrosine phosphorylation and was
not observed for the endogenous p52Shc. To minimize such
nonspecific interactions, we expressed TC45-D182A in lower
amounts. Similar amounts of TC45-D182A were precipitated,
and the Shc proteins were also expressed to similar levels in
each condition (Fig. 10B). We observed that association of the
TC45-D182A substrate-trapping mutant with GST-Shc and
GST-Shc Y317F, but not GST-Shc Y239F, Y239F/Y240F or
Y239F/Y240F/Y317F, was induced in response to EGF. The
results clearly demonstrate that Y239 of Shc is required for
association with the TC45-D182A substrate-trapping mutant
(Fig. 10B). These results therefore reinforce the hypothesis
that TC45 modulates specifically the phosphorylation of p52Shc
at tyrosine 239.
FIG. 9. TC45 does not modulate MAPK activity but inhibits the association
of p52Shc with Grb2. (A) COS1 cells were cotransfected with HA-tagged p42Erk2
plasmid and either TC45 or TC45-D182A mutant plasmid or vector alone.
Transfected cells were serum starved and either left unstimulated or stimulated
with EGF (100 ng/ml) for 20 min. Cells were then lysed, and HA-tagged p42Erk2
was precipitated and assayed by using myelin basic protein as substrate. Activity
was normalized for HA-Erk2 protein. Values shown are arbitrary units and are
means 6 standard errors of three independent experiments. (B) COS1 cells were
cotransfected (Cotfxn) with GST-Grb2 plasmid and either TC45 or TC45-D182A
plasmid or vector alone. Transfected cells were serum starved and either left
unstimulated or stimulated with EGF (100 ng/ml) for 15 min. Cells were then
lysed, and GST-Grb2 was precipitated with glutathione (GSH)-Sepharose 4B.
Precipitates were resolved by SDS-PAGE and immunoblotted with anti-Shc
antibody or anti-Grb2 antibody. The expression level of TCPTP in lysates was
analyzed by using antibody CF4.
FIG. 10. Tyrosine 239 of p52Shc is the major Grb2 binding site and is recog-
nized by TC45-D182A. (A) COS1 cells were transfected (Tfxn) with either the
wild type or the indicated tyrosine-to-phenylalanine phosphorylation site mu-
tants of GST-Shc. Transfected cells were serum starved, either left unstimulated
or stimulated with EGF (100 ng/ml) for 15 min, and lysed, and overexpressed
GST fusion protein was collected on glutathione (GSH)-Sepharose 4B. Precip-
itates were resolved by SDS-PAGE and immunoblotted with either anti-pTyr
antibody G98 or an anti-Shc or anti-Grb2 antibody. The apparent difference in
the association of Grb2 with the Y239F and Y239F/Y240F GST-Shc mutants was
not reproducible. (B) COS1 cells were cotransfected (CoTfxn) with the TC45-
D182A mutant and the wild type or the indicated tyrosine-to-phenylalanine
phosphorylation site mutants of GST-Shc. Cells were serum starved, either left
unstimulated or stimulated with EGF (100 ng/ml, 15 min), and then lysed, and
TC45-D182A was precipitated with specific antibodies. Precipitates were re-
solved by SDS-PAGE and immunoblotted with anti-Shc or anti-TCPTP (CF4)
antibody. The expression level of the GST-Shc proteins in the lysates was ana-
lyzed by using an anti-Shc antibody.















Previously we reported the development of a substrate-trap-
ping mutant for the identification of physiological PTP sub-
strates. Mutagenesis to alanine of the essential catalytic acid
residue which is invariant in the PTP family of enzymes, Asp
181 in PTP1B, resulted in a mutant enzyme which displayed a
Km comparable to that of the wild-type phosphatase but a kcat
which was reduced by a factor of ;105 (16). As such, this
mutant retains the ability to bind substrates but is catalytically
impaired and thus forms stable enzyme-substrate complexes.
In this study, we have used this approach to identify substrates
for the closely related phosphatase, TCPTP.
We have demonstrated that TCPTP and PTP1B, which are
promiscuous in vitro (25, 48, 56, 61), are highly specific in their
substrate preference when examined in a cellular context. Al-
though TC48 and PTP1B both localize to the ER and have
65% sequence identity overall (74% within their catalytic do-
mains), they recognized common and distinct substrates. Both
TC48-D182A and PTP1B-D181A substrate-trapping mutants
precipitated the EGFR and both PTP mutants accumulated
the EGFR at the ER, illustrating that complex formation oc-
curred within the intact cell and not postlysis. Importantly,
these complexes were not formed by the wild-type enzymes,
nor did the wild-type enzymes accumulate the EGFR at the
ER. In addition, it is known that vanadate functions as a PTP
inhibitor by modifying the essential nucleophilic cysteinyl res-
idue, characteristic of the PTP signature motif, which is located
at the active site of the enzyme (14, 28). We observed that
complex formation between the substrate-trapping mutant
PTPs and the pTyr proteins was disrupted when cells were
lysed in the presence of 2 mM vanadate, illustrating that the
interaction involved the PTP active site. Therefore the associ-
ation between the substrate-trapping mutants and pTyr pro-
teins most likely reflects an enzyme-substrate interaction.
In addition to the EGFR, the PTP1B substrate-trapping
mutant precipitated a pTyr protein with an apparent molecular
mass of ;60 kDa which was not precipitated by either the
TC48-D182A or the TC45-D182A substrate-trapping mutant.
The identity of the PTP1B 60-kDa substrate (previously re-
ferred to as p70 due to differences in Mr standards used for
SDS-PAGE [16]) remains unknown. We have tested but failed
to detect cross-reactivity with pTyr proteins within this molec-
ular weight range in assays using antibodies to c-Src, c-Yes,
paxillin, Sam68, p62Dok, protein kinase Cd, Raf-1, SHP-2, and
Shc. Using a TCPTP/1B chimera which relocalizes TC48 to the
precise location of PTP1B in the ER, we demonstrated that the
recognition of the 60-kDa substrate by PTP1B is due to inher-
ent specificity rather than differences in the ER microenviron-
ments of PTP1B and TCPTP. These data illustrate that intrin-
sic properties of individual PTPs contribute to their apparent
substrate specificity.
The function of PTP1B and TC48 remains to be defined.
Neither PTP1B nor TC48 affected the EGF-inducible p42Erk2
activity (data not shown), indicating that events triggered at the
plasma membrane are not modulated by these ER-localized
enzymes. Nevertheless, one of the functions of these highly
related PTPs may be to prevent inappropriate signalling from
the EGFR which may occur in a ligand-independent fashion as
the nascent receptor PTK undergoes posttranslational modifi-
cations in the ER (51). Furthermore, a number of transform-
ing, mutant receptor PTKs that display ligand-independent
activity, including mutant forms of the EGFR (15) and HER2
(27), have been identified. Interestingly, there are data to sug-
gest that some of these mutant PTKs signal while localized in
the ER (15, 27). Therefore, PTPs such as PTP1B and TC48
have the potential to attenuate such inappropriate signaling
events.
We have demonstrated that the differentially localized vari-
ants of TCPTP recognize distinct subsets of substrates, high-
lighting the additional importance of subcellular location in
determining substrate specificity. In contrast to the TC48-
D182A mutant, which precipitated only the EGFR, the TC45-
D182A substrate-trapping mutant precipitated four pTyr pro-
teins with apparent molecular masses of 50, 57, 64, and 180
kDa. We have identified two of the TC45 substrates as the
EGFR (p180) and p52Shc (p57). The 50- and 64-kDa pTyr
proteins that associated with TC45-D182A did not cross-react
with antibodies that recognize all three isoforms of Shc
(p46Shc, p52Shc, and p66Shc) and thus are neither p46Shc nor
p66Shc (43). The sites of phosphorylation in p46Shc and p66Shc
have yet to be defined. As discussed below, the phosphoryla-
tion of Shc on Y239 is essential for association with the TC45-
D182A mutant. Therefore one possibility is that the p46Shc and
p66Shc isoforms are not precipitated by TC45-D182A because
they are not efficiently phosphorylated on the residue equiva-
lent to Y239 in p52Shc. In addition to p52Shc and the EGFR, we
also tested antibodies to c-Src, c-Yes, paxillin, Sam68, p62Dok,
protein kinase Cd, Raf-1, SHP-2, and Nck but failed to detect
cross-reactivity with the 64- and 50-kDa pTyr proteins precip-
itated by TC45-D182A.
Although the EGFR and Shc are localized cytoplasmically,
TC45 is predominantly nuclear in randomly growing cells. We
observed that the pTyr proteins associated with TC45-D182A
only when cells were stimulated with EGF. This correlated
with the EGF-induced exit from the nucleus and accumulation
of the TC45-D182A substrate-trapping mutant in the cyto-
plasm. We were unable to detect an accumulation of wild-type
TC45 in the cytoplasm but could detect readily its ability to exit
the nucleus by heterokaryon analysis (41, 44) (data not shown).
Our ability to detect accumulation in the cytoplasm of the
TC45-D182A substrate-trapping mutant, but not the wild-type
TC45, is most likely attributable to the ability of the former to
generate stable complexes with pTyr substrates following EGF
stimulation which would prevent reentry into the nucleus.
Although the accumulation of the TC45-D182A substrate-
trapping mutant in the cytoplasm following EGFR activation
was reflected in the formation of stable complexes with pTyr
substrates, it is important to note that hyperphosphorylation of
proteins by constitutively activated Src (Y527F) was not suffi-
cient to induce the cytoplasmic accumulation of the phospha-
tase. Indeed, the phosphorylation of the TCPTP substrate Shc
on tyrosines 317 and 239/240 by the activated Src Y527F (data
not shown) did not induce the accumulation of TC45-D182A
in the cytoplasm. These results suggest that gratuitous tyrosine
phosphorylation of proteins, including TCPTP substrates, is
not sufficient to trigger the change in localization of the phos-
phatase, but rather that specific signaling events that are de-
pendent on the activated EGFR may be required.
In light of the fact that the TC45-D182A substrate-trapping
mutant recognized both the EGFR and p52Shc, we were sur-
prised at first that TC45 did not modulate the MAPK pathway.
EGFR activation results in transautophosphorylation of the
C-terminal tail of the receptor, creating specific binding sites
for the recruitment of various SH2-containing proteins, includ-
ing Shc and Grb2 (2, 11, 42, 43). Grb2 associates, via its SH2
domains, directly with the receptor or to pTyr Shc, providing a
link to SOS and MAPK activation (6, 33, 45–47, 49). EGFR
mutants lacking the autophosphorylation sites no longer bind
Grb2 but maintain their ability to phosphorylate Shc and to
activate the Ras/MAPK pathway (20, 26, 34). Although numer-
ous studies have demonstrated the importance of Grb2 in














stimulating the Ras/MAPK pathway (6, 18, 36, 46), the relative
importance of direct binding of Grb2 to Y1068 of the EGFR
(2) compared to binding and signaling via Shc (50), remains
unclear. The importance of Shc in activation of the Ras/MAPK
pathway by EGF is illustrated by the fact that overexpression of
the Shc Y317F mutant inhibits the EGF-induced activation of
MAPK in NIH 3T3 cells expressing an EGFR in which the
autophosphorylation sites have been mutated (20, 22). In ad-
dition, overexpression of p52Shc in HeLa cells stimulates EGF-
induced MAPK activity (38). Considering that TC45 inhibited
directly the association of p52Shc with Grb2 without affecting
p42Erk2 activation, our studies suggest that Shc may participate
in signaling events involving Grb2 that are independent of the
MAPK pathway.
Consistent with recently published reports (21, 22, 24, 59),
we found that Shc is phosphorylated not only on tyrosine 317
but also on tyrosines 239 and 240 in COS1 cells and that the
Y239 site is a Grb2 binding site. We have demonstrated that
TC45 modulates the association of p52Shc with Grb2 and that
the TC45-D182A trapping mutant specifically recognizes Shc
phosphorylated on tyrosine 239. Therefore, TC45 may modu-
late specifically the association of Grb2 with Y239 on p52Shc
and the signaling pathways emanating from this site. However,
we observed that TC45 did not affect EGF-induced activation
of p42Erk2, indicating that despite the fact that Grb2 binds to
pY239, the signals emanating from this site do not contribute
to MAPK activation. These results provide evidence for bifur-
cation of signaling pathways at the level of Shc and are con-
sistent with recent studies which have demonstrated that the
Y239/Y240 site does not contribute to EGF-induced MAPK
activity but nonetheless is important in EGF-induced mitogen-
esis (22). The Shc Y239/Y240 site also contributes to interleu-
kin-3-dependent myc expression in the BaF3 pro-B-cell line
(21). However, in NIH 3T3 cells stably overexpressing a trun-
cated mutant EGFR which selectively phosphorylates Shc, the
Y239F/Y240F Shc mutant does not modulate EGF-induced
myc expression under conditions where it does inhibit mito-
genesis (22). Therefore, the role of the Y239/Y240 site in
EGF-induced mitogenesis remains to be elucidated. To further
our understanding of TC45 function, additional studies will be
needed to elucidate the role of the p52Shc Y239/Y240 site in
EGF-induced signaling in combination with the identification
of the 50- and 64-kDa pTyr proteins precipitated by TC45-
D182A. The identification of these substrates will allow a bet-
ter understanding of how the Y239/Y240 site can bind Grb2
without stimulating the MAPK cascade. In addition to Grb2,
we have observed the association of pTyr proteins of ;60 and
62 kDa with GST-Shc phosphorylated on Y239, but not Y317,
following EGF stimulation (data not shown). Others have re-
ported that phosphopeptides modeled on the Y239/Y240 site
bind pTyr proteins from v-Src-transformed cells (59). Until
these additional proteins are characterized, it will be difficult to
evaluate the contribution of Grb2 binding at Y239 to the spec-
ificity of signaling.
In this study, we have demonstrated that the ubiquitous and
closely related PTPs TCPTP and PTP1B are highly specific
enzymes that recognize distinct, as well as overlapping, sub-
strates and that localization of the alternatively spliced TCPTP
variants is critical for their substrate recognition. We show that
in contrast to signaling molecules such as MAPKs and the
STATs, which translocate to the nucleus following growth fac-
tor or cytokine stimulation (8, 29), the 45-kDa TCPTP exits the
nucleus in response to EGF and gains access to cytoplasmic
substrates. One of the specific cellular substrates of the 45-kDa
TCPTP is the adaptor protein p52Shc, phosphorylated at the
Y239 site. Therefore, the 45-kDa TCPTP recognizes distinct
sites within defined substrates and thus may regulate specific
signaling events emanating from such molecules.
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